Théo Risopoulos

The Flare Threat Exposure Management (TEM) solution empowers organizations to proactively detect, prioritize, and mitigate the types of exposures commonly exploited by threat actors. Our platform automatically scans the clear & dark web and prominent threat actor communities 24/7 to discover unknown events, prioritize risks, and deliver actionable intelligence you can use instantly to improve security. Flare integrates into your security program in 30 minutes and often replaces several SaaS and open source tools. Learn more by signing up for our free trial: https://try.flare.io/free-trial/

Classcraft is a free online, educational role-playing game that teachers and students play together in the classroom. By using many of the conventions traditionally found in games today, students can level up, work in teams, and earn powers that have real-world consequences. Acting as a gamification layer around any existing curriculum, the game transforms the way a class is experienced throughout the school year. Classcraft is available via web browser and native apps for iOS and Android devices. Classcraft (www.classcraft.com) has received broad acceptance, along with a number of education and design nominations and awards.

Icentia combine des activités de développement dappareils médicaux et de services danalyse. Nous fournissons une gamme de tests médicaux innovateurs pour les institutions de santé. Notre mission est daider les institutions de santé à devenir plus efficaces en fournissant des solutions avant-gardistes dans le domaine des tests médicaux. -- Icentia is a combined medical devices manufacturer and service company providing a line of medical testing innovations. Our mission is to help healthcare institutions become more efficient by providing unique solutions easing the process of medical testing.

Moonshot Health is an early stage company developing impactful products based on scientifically validated Digital Biomarkers. We look at all the aspects of everyday life that can affect a persons health to develop Digital Biomarkers. Our end goal is to provide people with products that support their journey across the full-care continuum – from prevention, to screening & diagnostic, treatment, and management.

Seido Capital is an early and growth stage healthcare investor active in North America with 150 M$ AuM. Building on 20 years of top-quartile track record, we partner with visionary entrepreneurs to address critical challenges through groundbreaking innovation in biotechnology, medical devices and AI tools for the life sciences industry.

Theodorus invests in early stage companies based on proprietary disruptive technologies, leading financing rounds from inception to series A and above

The Flare Threat Exposure Management (TEM) solution empowers organizations to proactively detect, prioritize, and mitigate the types of exposures commonly exploited by threat actors. Our platform automatically scans the clear & dark web and prominent threat actor communities 24/7 to discover unknown events, prioritize risks, and deliver actionable intelligence you can use instantly to improve security. Flare integrates into your security program in 30 minutes and often replaces several SaaS and open source tools. Learn more by signing up for our free trial: https://try.flare.io/free-trial/

Domain Therapeutics, a clinical-stage global biopharmaceutical company, focused on developing innovative immunotherapies targeting G Protein-Coupled Receptors (GPCRs), one of the most important drug target classes, to unlock new possibilities in cancer. As a leader in GPCRs in immuno-oncology, Domain sees cancer differently, using a precise biomarker strategy to address the specific needs of patients based on unique signatures of individual cancers. Two decades of solid experience in GPCR drug discovery, validated by multiple pharma partnerships, associated to a target identification and drug discovery platform enable the Company to enhance the understanding of cancer and deliver innovative immunotherapies to patients. Domain’s proprietary programs include DT-7012, a Treg-depleting CCR8 antibody, DT-9045, a first-in-class PAR2 negative allosteric modulator, and DT-9081, an EP4 receptor antagonist alongside the M1069, an A2aR/A2b receptor antagonist identified in partnership with Merck KGaA. The company has also an optimized pipeline of best-in-class and first-in-class GPCR targets selected through Domain’s proprietary cross-validation drug discovery and development platform.

Students are in a unique position to challenge the status quo and solve complex issues. In short, university years are an entrepreneurial sweet spot. At Front Row Ventures, we want our peers to capitalize on their potential. We want to help you launch unthinkable ventures. Our team of student investors will assist you in every step of your entrepreneurial journey. Not only do we invest $50K in our portfolio companies, we create irreplaceable value for our student startups. The bigger picture is to spread the startup and venture capital culture across Canadian university campuses, and offer our strong and diverse community amazing opportunities. Be part of it! // Personne n’est mieux placé pour défier le statu quo et résoudre des enjeux complexes que des étudiants. Les universités forment un terreau entrepreneurial incroyablement fertile. Chez Front Row Ventures, nous poussons nos pairs à capitaliser sur leur propre potentiel. Nous les aidons à démarrer des startups époustouflantes. Les entrepreneurs peuvent compter sur le support indéfectible de notre équipe d’investisseurs étudiants. Bref, la valeur ajoutée que nous générons pour nos startups étudiantes dépasse largement les $50K investis en elles. À plus grande échelle, nous propageons la culture des startups et du capital de risque à travers tous les campus Canadiens. Nous offrons à notre communauté des opportunités hors du commun. Front Row Ventures est une expérience unique. Rejoins le mouvement. Tire-toi une chaise!